Biopharma & Life Sciences
Pliant Therapeutics Executive Compensation (FY25)
PLRX · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 11, 2026
142 figures on this page: 137 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
The disclosed peer group names 4D Molecular Therapeutics, Akero Therapeutics, Alector, Arcturus Therapeutics and Crinetics Pharmaceuticals, among others. Separately, total compensation for Bernard Coulie, President, Chief Executive Officer and Director, came to $5,462,901 in fiscal 2025, and shareholders supported the say-on-pay proposal with 51.2% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025, and for fiscal 2025, the company reported 4 named executive officers. Disclosures span fiscal 2025 only.
This company is not required to report a chief executive pay ratio.
Frequently asked questions
Answers drawn from the data on this page.
Who is Pliant Therapeutics' chief executive and what were they paid?
Total compensation for Bernard Coulie, President, Chief Executive Officer and Director, came to $5,462,901 in fiscal 2025.
What was Pliant Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 51.2% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in Pliant Therapeutics' peer group?
The disclosed peer group names 4D Molecular Therapeutics, Akero Therapeutics, Alector, Arcturus Therapeutics and Crinetics Pharmaceuticals, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Bernard Coulie President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Eric Lefebvre Former Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Keith Cummings Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Minnie Kuo Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Bernard Coulie | OTHER | — | — | — | — | — | — | ◇ |
| Eric Lefebvre | OTHER | — | — | — | — | — | — | ◇ |
| Keith Cummings | OTHER | — | — | — | — | — | — | ◇ |
| Minnie Kuo | OTHER | — | — | — | — | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Eric Lefebvre | Option | ◇ | — | ◇ | 1/23/2034 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/23/2035 | |
| Option | ◇ | — | ◇ | 1/25/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/26/2032 | |
| Keith Cummings | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 1/25/2033 | |
| Option | ◇ | — | ◇ | 1/26/2032 | |
| Option | ◇ | — | ◇ | 1/23/2034 | |
| Option | ◇ | — | ◇ | 1/23/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Minnie Kuo | Option | ◇ | — | ◇ | 1/23/2034 |
| Option | ◇ | — | ◇ | 9/14/2033 | |
| Option | ◇ | — | ◇ | 1/23/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Bernard Coulie | Option | ◇ | — | ◇ | 1/26/2032 |
| Option | ◇ | — | ◇ | 1/25/2033 | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/23/2034 | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Hoyoung Huh | ◇ | — | ◇ | — | — | — | ◇ |
Steve Krognes | ◇ | — | ◇ | — | — | — | ◇ |
Katharine Knobil | ◇ | — | ◇ | — | — | — | ◇ |
Gayle Crowell | ◇ | — | ◇ | — | — | — | ◇ |
Thomas McCourt | ◇ | — | ◇ | — | — | — | ◇ |
David Pyott | ◇ | — | ◇ | — | — | — | ◇ |
Darren Cline | ◇ | — | ◇ | — | — | — | ◇ |
Suzanne Bruhn | ◇ | — | ◇ | — | — | — | ◇ |
John Curnutte | ◇ | — | ◇ | — | — | — | ◇ |
Smital Shah | ◇ | — | — | — | — | — | ◇ |
Bernard Coulie served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Stock Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 4D Molecular Therapeutics FDMT
- Akero Therapeutics AKRO
- Alector ALEC
- Arcturus Therapeutics ARCT
- Crinetics Pharmaceuticals CRNX
- Day One Biopharmaceuticals DAWN
- Disc Medicine IRON
- Erasca ERAS
- IDEAYA Biosciences IDYA
- IGM Biosciences IGMS
- iTeos Therapeutics ITOS
- KalVista Pharmaceuticals KALV
- Keros Therapeutics KROS
- Kura Oncology KURA
- Kymera Therapeutics KYMR
- Olema Pharmaceuticals OLMA
- Protagonist Therapeutics PTGX
- Replimune Group REPL
- Rocket Pharmaceuticals RCKT
- Scholar Rock SRRK
- Structure Therapeutics, Inc. GPCR
- Viridian Therapeutics VRDN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 13, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 7, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 16, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Pliant Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pliant Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Pliant Therapeutics recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
142 figures on this page: 137 cited to the filing that reported them, 5 calculated from figures it prints.
137 cited to the filing
5 calculated from the filing
Documents cited
- 0001746473-26-000092
- 0001746473-26-0000762025 Outstanding Equity Awards at Fiscal Year-End · 2025 Summary Compensation Table · DIRECTOR COMPENSATION · Non-Employee Director Compensation Policy · and 1 more section
- 0001746473-25-000105
- 0001746473-24-000084
- 0001746473-23-000036
- 0001193125-22-176473
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pliant Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/PLRX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pliant Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Pliant Therapeutics discloses
The companies named in PLRX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}